Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

Taichung Veterans General Hospital

Status: Completed

Conditions: Cardiotoxicity; Drug-Related Side Effects and Adverse Reactions (MeSH Term); Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung); Egfr Tyrosine Kinase Inhibitor

Treatments: Other: EGFR tyrosine kinase inhibitor; Drug: EGFR-TKI

Study type: Observational

Funder types: Other

Identifiers

NCT07267247

VGHTC-CM-MHP-20250918

Details and patient eligibility

About

This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.

Enrollment: 100 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients with advanced or recurrent EGFR-mutant NSCLC receiving EGFR-TKI treatment

Exclusion criteria

• NIL